Fred Alger Management released its fourth-quarter 2025 investor letter, highlighting the strong performance of the Alger Small Cap Focus Fund. The US equity market ended the quarter on a high note, with the S&P surging 2.7%. The fund outperformed the Russell 2000 Growth Index, with sectors like Utilities and Financials contributing to its relative performance. However, the enthusiasm for AI investment is facing doubts due to various challenges. In the letter, UniQure N.V. (NASDAQ:QURE) was mentioned as a promising stock, with a one-month return of -8.57% and a 52-week gain of 62.56%. UniQure N.V. (NASDAQ:QURE) is a biotechnology company developing treatments for rare diseases, with a market capitalization of $1.42 billion. The company’s stock closed at $22.84 per share on November 18, 2025.

In its investor letter, Alger Small Cap Focus Fund discussed UniQure N.V. (NASDAQ:QURE) and its development of AMT-130, a gene therapy for Huntington’s disease. Despite a surge in shares after promising Phase 1/2 data, regulatory uncertainty caused a decline in stock value. UniQure N.V. (NASDAQ:QURE) was held by 59 hedge fund portfolios in the third quarter, with $3.7 million in revenue reported in Q3 2025. While UniQure N.V. (NASDAQ:QURE) shows potential, other AI stocks may offer greater upside with less risk.

In another article, UniQure N.V. (NASDAQ:QURE) was mentioned as a promising stock to buy under $50. For more investor letters and insights, visit the hedge fund investor letters Q4 2025 page.

Read more at Yahoo Finance: Here’s Why uniQure (QURE) Fell in Q3